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ABSTRACT 
Introduction Hypoplastic left heart syndrome (HLHS) is a severe cardiac 
malformation, fatal in the neonatal period in the absence of immediate care. 
Palliative surgery for HLHS has been available in Sweden since 1993. The 
outcome has improved over time, but there is still significant mortality. It has 
been suggested that fetal valvuloplasty in fetal aortic stenosis may prevent 
progression to HLHS. Home monitoring of oxygen saturation has been 
suggested as a method to improve survival after the initial surgery. 
Aims The aims were to investigate the survival rate of patients born with 
HLHS in Sweden from1990 to 2010, and to evaluate fetal valvuloplasty of 
the aortic valve as a method of preventing HLHS. A third aim was to evaluate 
the importance of home monitoring as a method to improve survival after the 
initial surgery.  
Methods The complete national cohort of patients with HLHS was 
identified through national databases. Changes in incidence and 
transplantation-free survival were calculated and analyzed in relation to risk 
factors for death. The natural history of fetal aortic stenosis and the efficacy 
of a fetal intervention were investigated in two retrospective multi-center 
studies. Home monitoring was evaluated in an experimental study and 
survival was compared with a historical cohort.  
Results and conclusions The overall 10-year transplantation-free survival 
of patients with HLHS increased from 40 % 1993–2000 to 63 % 2001–2010. 
Female gender was identified as a significant risk factor. The incidence at 
birth decreased from 15.4 to 8.4 per 100,000. The proportion of liveborn 
neonates with HLHS undergoing surgery increased from 50 % to 70 %. Fetal 
intervention with balloon dilatation of the aortic valve improved postnatal 
survival but did not prevent progression to HLHS. Home monitoring of 
oxygen saturation was considered lifesaving in a number of individuals but 
there was no statistical difference in survival compared to a historical cohort.  
 
Keywords: Hypoplastic left heart syndrome, aortic valve stenosis, fetal heart, 
fetal therapies, outcome studies, survival analysis, epidemiology, incidence, 
prenatal diagnosis, pregnancy outcome.  
 
 
ISBN978-91-7833-025-6 (PRINT)  
ISBN 978-91-7833-026-3 (PDF)  
  
  2
LIST OF PAPERS  
This thesis is based on the following studies, referred to in the text by their 
Roman numerals. 
 
I. Öhman A, Strömvall-Larsson E, Nilsson B and Mellander 
M. Pulse oximetry home monitoring in infants with single 
ventricle physiology and a surgical shunt as the only source 
of pulmonary blood flow. Cardiology in the Young. 
2013;23:75–81. 
II. Gardiner H, Kovacevic A, Tulzer G, Sarkola T, Herberg U, 
Dangel J, Öhman A, Bartrons J, Carvalho J, Jicinska H, 
Fesslova V, Averiss I, Mellander M and Fetal Working 
Group of the AEPC. Natural history of 107 cases of fetal 
aortic stenosis from a European multicenter retrospective 
study. Ultrasound in Obstetrics and Gynecology. 
2016;48:373-381. 
III. Kovacevic A, Öhman A, Tulzer G, Herberg U, Dangel J, 
Carvalho JS, Fesslova V, Jicinska H, Sarkola T, Pedroza C, 
Averiss I, Mellander M and Gardiner HM. Fetal 
hemodynamic response to aortic valvuloplasty and postnatal 
outcome: a European multicenter study. Ultrasound in 
Obstetrics and Gynecology. 2017. doi: 10.1002/uog.18913 
IV. Öhman A, El-Segaier M, Bergman B, Hanseus K, Malm T, 
Nilsson B, Pivodic A, Rydberg A, Sonesson SE, Mellander 
M. The changing epidemiology of hypoplastic left heart 
syndrome. Results of a national Swedish cohort study. 
(Submitted). 
V. Öhman A, El-Segaier M, Bergman B, Hanseus K, Malm T, 
Nilsson B, Pivodic A, Rydberg A, Sonesson S, Mellander 
M. Transplantation-free survival and risk factors for death or 
heart transplantation after Norwood surgery in a complete 
national cohort of patients with HLHS in Sweden 1993–
2010. (Submitted). 
 
  
 3 
LIST OF CONTENT 
ABSTRACT .............................................................................. 1 
List of papers ............................................................................ 2 
Abbreviations ............................................................................ 5 
Definitions ................................................................................. 6 
Introduction .............................................................................. 7 
Aims .......................................................................................... 9 
Hypoplastic left heart syndrome (HLHS) ................................ 10 
Definition ...................................................................................... 10 
Embryology and development ...................................................... 10 
Morphology .................................................................................. 11 
Single ventricle palliation ............................................................. 12 
Incidence ...................................................................................... 13 
incidence in relation to gender ...................................................... 14 
Prenatal detection rate and outcome of pregnancy ....................... 14 
Outcome ....................................................................................... 15 
Modification of the Norwood procedure with introduction of the 
right-ventricle-to-pulmonary-artery-shunt (Sano shunt) ........................ 16 
Intermediate-term transplantation-free survival after Norwood 
surgery and interaction with shunt type ................................................. 17 
Interstage mortality between stages I and II ..................................... 17 
Optimal timing of the second stage in the palliative surgical 
treatment of HLHS ................................................................................. 18 
Outcome and risk factors for death after stage II surgery ................. 19 
Outcome after stage III surgery......................................................... 19 
Survival after Norwood surgery ................................................... 20 
Ethical considerations ................................................................... 21 
Intention-to-treat, comfort care or termination of pregnancy (ToP) . 21 
Fetal aortic stenosis ................................................................. 23 
Definition ...................................................................................... 23 
Incidence ...................................................................................... 23 
Natural history ............................................................................. 23 
Pathophysiology ........................................................................... 24 
Hemodynamics ............................................................................. 25 
Hydrops ............................................................................................. 25 
Fetal valvuloplasty ........................................................................ 25 
  4
Procedural information ..................................................................... 26 
Changes in pathophysiology and hemodynamics following fetal 
valvuloplasty ..................................................................................... 27 
Fetal echocardiography as predictor of outcome.......................... 27 
Repeatability (intra-observer variability) and reproducibility 
(inter-observer variability) of fetal echocardiographic measurements
 ......................................................................................................... 28 
Patients and methods ............................................................... 30 
Study design................................................................................. 30 
Study populations, exposures and outcomes ................................ 33 
Conducting research using national register data ........................ 34 
Ethical considerations in research studies .................................... 36 
Statistical methods ................................................................... 39 
Statistical measurements .............................................................. 39 
measurements of incidence .......................................................... 40 
Reducing bias and confounding in observational studies using 
propensity score ................................................................................ 40 
Results ..................................................................................... 44 
Survival papers I - V .................................................................... 45 
Discussion ................................................................................ 46 
Conclusions and Future perspectives ....................................... 49 
Sammanfattning på svenska .................................................... 51 
Acknowledgements .................................................................. 53 
References ............................................................................... 55 
 
  
 5 
ABBREVIATIONS 
AA Aortic atresia 
AEPC Association for European Pediatric and Congenital Cardiology 
AoA Aortic arch 
AoS, AS Aortic stenosis 
AV-valve Atrioventricular valve 
BCPC Bidirectional cavopulmonary connection 
BDG Bidirectional Glenn operation 
BT-shunt Blalock-Taussig shunt 
BV Biventricular 
CC Comfort care 
EFE Endocardial fibroelastosis 
eHLHS Evolving hypoplastic left heart syndrome 
FO Foramen ovale 
FV Fetal valvuloplasty 
HLHS Hypolastic left heart syndrome 
HR Hazard ratio 
HTX Heart transplantation 
ICD-9,10 International Statistical Classification of Diseases and Related Health Problems 
IPTW Inverse probability of treatment weighting 
LV Left ventricle 
MA Mitral atresia 
MS Mitral stenosis 
NH Natural history 
NYHA New York Heart Association 
OR Odds ratio 
PS Propensity score 
RCT Randomized controlled trial 
sIUD Spontaneous intra uterine death 
TCPC Total cavopulmonary connection 
ToP Termination of pregnancy 
UV Univentricular 
US United States of America 
VSD Ventricular septal defect 
z-score Standard score 
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DEFINITIONS 
30-day surgical mortality Death occurring within 30 days after surgery.  
Anatomy and morphology The study of the structure and development of organisms. 
Bias The result of a systematic error in the design or conduct of a 
study.  
Confounder A confounding factor influences both the exposure and the 
outcome.  
Congenital Referring to conditions that are present at birth, regardless of 
their causation. 
Embryology The study of fetal development. Three major parts; the first 
three weeks, the embryonic period (third to eighth week) and 
the fetal period (third month to birth).  
Hypoplasia Incomplete development or underdevelopment of an organ or 
tissue. 
Information bias Information bias results from either imperfect definition of 
study variables or flawed data collection procedures.  
Interstage mortality Death occurring between stage I and stage II in the single 
ventricle palliation. 
Interstage mortality (Paper I) Death occurring between stage I and stage II after discharge 
from hospital. 
Interstage mortality (Paper V) Death occurring between 30 days after stage I before stage II   
Outcome The result of an event or process. 
Physiology The study of function of living organisms. 
Selection bias A systematic error in recruitment or retention of study 
subjects.  
Stage I Norwood or hybrid surgery 
Stage II BDG  
Stage III TCPC or Fontan completion 
Syndrome A combination of symptoms resulting from a single cause or 
commonly occurring together as to constitute a distinct 
clinical picture.  
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INTRODUCTION 
Left-sided obstructive lesions include single or multiple obstructions on one or 
more levels of the left side of the heart. This thesis will present research related 
to fetal aortic stenosis and hypoplastic left heart syndrome. The natural history 
of fetal aortic stenosis and the potential of fetal cardiac intervention to prevent 
from evolution of hypoplastic left heart syndrome will be discussed. The 
epidemiology and outcome for fetuses and neonates with hypoplastic left heart 
syndrome will be elucidated. The efficacy of home monitoring of oxygen 
saturation in a cohort of different single ventricle lesions was observed and 
will be presented.  
The PhD project started with the study reported in Paper I, evaluating home 
monitoring of oxygen saturation in patients with single-ventricle physiology 
and a shunt as the only source of pulmonary blood flow. The study was an 
experimental study, aiming to evaluate the influence of the implementation of 
intensified surveillance of patients between stage I and stage II surgery through 
home monitoring of oxygen saturation. Papers II and III were the results of a 
project on fetal aortic stenosis initiated by the fetal working group of AEPC. 
The study took off during an AEPC meeting in Granada in 2011. At that time, 
the fetal working group had observed a growing interest in fetal interventions, 
especially balloon dilation of the aortic valve. There were some promising 
results, but the scientific evidence was weak. To address this experienced lack 
of evidence, the fetal working group of AEPC decided to form a research group 
to study fetal aortic stenosis. The plan, as it was formed at the Granada 
meeting, was to conduct two parts of the project, a retrospective part and a 
prospective study. The results of the former would guide the design of the 
latter. At the time I got involved, there was already a study design and a study 
protocol in place. I visited London in June 2011 to receive information and to 
discuss some practical issues. I was assigned to collect data from the Nordic 
countries, Bonn, and Italy. The procedure to perform fetal cardiac intervention 
was not practiced in any of the Nordic countries.  
At the time of the start of the study, I was working in Stockholm and 
identified cases of fetal aortic stenosis from the local fetal databases. While 
collecting the data, I discovered that fetal aortic stenosis was a rare condition 
and that most of the identified cases were far along the road towards HLHS. 
The majority of identified cases were counseled by the fetal cardiologist as 
future univentricular hearts and many chose to terminate the pregnancy. I also 
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observed that the clinic had neonates with critical aortic stenosis who 
underwent biventricular repair and none of them had a prenatal diagnosis. This 
observation made me realize that cases with fetal aortic stenosis and a normal 
or dilated left ventricle with a likely UV circulatory outcome but with BV 
potential was rare in our population of fetuses while a postnatal diagnosis of 
critical aortic stenosis and BV outcome was more common.  
The primary aim of performing fetal valvuloplasty is to improve postnatal 
survival by achieving BV circulation. To investigate the survival probability 
for liveborn neonates with UV circulation due to left-sided hypoplasia, we 
decided to identify all cases with HLHS born in Sweden and observe their 
outcome. We chose to limit the inclusion criteria of the national cohort to 
patients with the morphology of aortic atresia versus aortic stenosis. The 
reason to do so was the aim to compare outcomes and exposure factors for 
patients with as similar morphology and physiology as possible. We feared that 
including AS/MS would make the comparison more difficult and the 
morphology (AS/MS) would possibly be a factor more important influencing 
outcome than other risk factors aimed to study.  
This thesis includes chapters on the specified cardiac malformations 
HLHS/AA and fetal aortic stenosis. Included in the chapter on fetal aortic 
stenosis is a part where details on the technical procedure is described and a 
part on fetal echocardiography as a predictor of outcome. This is followed by 
chapters on the methodology and statistical methods. At the end, there is a 
discussion including the results from all the papers, as well as conclusions and 
future perspectives.  
Tables 1–3 refer to tables in the thesis itself. Figures 1-2 are referred to 
figures in the thesis while figures included in any of the papers are referred to 
as the Roman numeral of the paper and the number of the figure in the paper. 
Tables A–C are found in the Appendix and provide overviews of the included 
studies.  
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AIMS 
The specified aims for each paper are listed below.  
 
I. The primary aim was to evaluate whether daily measurement 
of oxygen saturation at home between stage I and stage II 
would be beneficial to patients through earlier detection of 
impending shunt occlusion. A secondary aim was to examine 
parents’ experiences with home monitoring. 
II. The primary aim was to report the spectrum of fetal left heart 
morphology and physiology, pregnancy outcome, survival 
and final circulatory pathways in a natural history cohort of 
aortic stenosis (NH). A secondary aim was to test previously 
published criteria for evolving HLHS and identify ideal 
candidates for fetal valvuloplasty (FV) in this population of 
fetuses by comparing predicted with observed outcome. 
III. The primary aim was to assess FV efficacy by comparing 
survival and postnatal circulation between FV and NH 
cohorts. Secondary outcomes were hemodynamic change and 
left heart growth.  
IV. The primary aim was to describe the incidence and evaluate 
the possible change in incidence of HLHS/AA in Sweden. A 
secondary aim was to investigate factors influencing whether 
or not surgery was performed. 
V. The primary aim was to describe the outcome for patients 
with HLHS/AA who underwent surgery and to analyze 
factors with correlation to outcome. 
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HYPOPLASTIC LEFT HEART SYNDROME (HLHS) 
DEFINITION  
Hypoplastic left heart syndrome (HLHS) defines a constellation of findings 
with severe obstructions and underdevelopment of the left-sided structures of 
the heart.  The cardiac anomaly was first described by Lev [1] and Noonan and 
Nadas [2] who introduced the term HLHS in 1958. In the original work, a 
common atrioventricular valve was included as a variant of HLHS while the 
modern definition excludes a common atrioventricular junction [2, 3].  
In the current version of the International Statistical Classification of 
Diseases (ICD-10), HLHS is defined as “atresia, or marked hypoplasia of the 
aortic orifice or valve, with hypoplasia of ascending aorta and defective 
development of left ventricle, with mitral valve stenosis or atresia” [4, 5]. The 
term “classic HLHS” has been used to describe “left ventricular hypoplasia 
associated with mitral and aortic valve hypoplasia or atresia and hypoplastic 
ascending aorta” [6, 7].  
The physiology of HLHS is functionally univentricular circulation in which 
the right ventricle provides for both systemic and pulmonary blood flow while 
the left ventricle contributes not at all or very little to the cardiac output.  
The three surgical palliative stages for HLHS are the Norwood or hybrid 
procedure during the neonatal period (Stage I) followed by bidirectional Glenn 
at 4-6 months of age (Stage II) and finally a Fontan procedure at 2-4 years of 
age (Stage III) [8].  
EMBRYOLOGY AND DEVELOPMENT  
There are three main theories suggested to explain the origin of HLHS. The 
embryological theory, the “flow” theory and the theory of fetal aortic stenosis 
evolving to HLHS. The embryological theory is related to the early stage in 
development, controlled by the interplay of genetic expression and 
environmental factors [9, 10]. Normally, the formation of the aortic valve 
includes the formation of the aortic sac, which is covered with cells from the 
endocardial cushions derived from the neural crest. When this process fails, 
the formation of the aortic valve or mitral valve can be incomplete. The atresia 
of the aortic or mitral valves results in underdevelopment of all left-sided 
structures including the left atrium, left ventricle, ascending aorta, and aortic 
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arch, with or without coarctation. A recent report on the genetic background of 
HLHS states that it is a multigenic and genetically heterogeneous condition 
where mutations in specific areas of the genome mediate left ventricular 
hypoplasia and aortic valve abnormalities in early development [11]. 
Environmental factors such as maternal exposure to toxic agents and seasonal 
viruses have been described as increasing the incidence of HLHS in the 
population [12, 13]. The second explanation is related to disrupted flow due to 
malalignment of the interatrial septum. According to this theory, the 
consequences of the disturbed flow result in poor growth and hypoplasia of 
left-sided structures and HLHS will develop [14]. The third theory is related to 
fetal aortic stenosis as the primary cardiac lesion evolving into HLHS at birth. 
This development will be further discussed in the following main chapter.  
MORPHOLOGY 
HLHS can be the constellation of aortic stenosis (AS) with mitral stenosis 
(AS/MS), or aortic atresia with mitral stenosis (AA/MS) or mitral atresia 
(AA/MA). The abbreviation HLHS/AA will in this work be used for the two 
combinations of HLHS with AA. AS/MS is a heterogeneous malformation 
with variable expressions. The left ventricle can be dilated or normal to 
hypoplastic in size, with or without endocardial fibroelastosis (EFE). The 
outcome of the combination AS/MS can be bi- or univentricular depending on 
the size and function of the left-sided structures. When there is AA, the 
ventricle is always small, either rounded and thick or slit-like in shape. The 
typical appearance of AA/MS is of a rounded and thick left ventricle with a 
lining of EFE and sometimes with ventriculo-coronary arterial connections 
[15, 16]. AA/MA is more often seen in combination with a slit-like left 
ventricle without EFE, and rarely with ventriculo-coronary arterial connections 
[17]. The outcome of HLHS/AA is always univentricular circulation, since the 
absence of a left outflow tract and left ventricle cannot be compensated for. 
The presence of a VSD creates a fourth possibility, but this morphology will 
not be further discussed here.  
EFE is a phenomenon seen as a white lining of the inner wall of the left 
ventricle when examined using echocardiography in fetal and postnatal life 
[18]. It is seen in conjunction with HLHS and in relation to viral myocarditis 
and autoantibody-mediated myocardial disease in the fetus [19]. The finding 
of EFE in HLHS is described as being more frequent in hearts that have 
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elevated end-diastolic pressure, as in AS or AA, and some patency of the mitral 
valve rather than in AA/MA [20]. The presence of EFE has been considered a 
reason for stunted growth in evolving HLHS, leading to attempts to remove it 
in postnatal surgery to improve diastolic function and growth [21, 22].  
The fetus and the neonate with left-sided obstructive lesions may survive if 
the right side of the heart can support systemic output through the ductus 
arteriosus. The right ventricle will continue to be the systemic ventricle after 
birth and after surgical palliation. The right ventricle, which normally handles 
various amounts of volume-loading in a low-pressure setting, has to cope with 
both high volume- and high-pressure load. Variations in morphology of the 
tricuspid valve in conjunction with HLHS have been reported, as well as 
changes in right ventricular geometry [23, 24].The conditions for the right 
ventricle are challenging, and the overall function of univentricular circulation 
is dependent on a well-functioning right ventricle and tricuspid valve [25] and 
a low enough pulmonary vascular resistance.  
SINGLE VENTRICLE PALLIATION 
The treatment options for HLHS are a palliative surgical three-stage pathway 
to a Fontan circulation or neonatal cardiac transplantation. The first stage in 
single-ventricle palliation is either the Norwood procedure or a hybrid 
procedure. The surgical technique of the Norwood procedure is described in 
Paper V. The second stage in the palliative pathway for HLHS is performed by 
connecting the systemic venous return from the upper part of the body to the 
pulmonary circulation. This can be done either through the right atrium, as in 
the Hemi-Fontan procedure, or through a connection between the superior vena 
cava and the pulmonary artery branches. This results in the bidirectional 
cavopulmonary connection (BCPC), also referred to as the bidirectional Glenn 
procedure (BDG) [26]. The hemodynamic advantages include decreased 
volume load of the right ventricle and improved oxygen saturation. The risk of 
thrombosis is less compared to the shunt-dependent circulation after the 
Norwood procedure. The third and final stage in the palliative pathway is 
connecting the venous return from the lower part of the body to the pulmonary 
circulation. This can be achieved by either an intracardiac or an extracardiac 
tunnel with or without fenestration. Fenestration permits unloading of pressure 
and volume from the pulmonary venous circulation. The surgical procedure is 
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commonly referred to as “total-cavopulmonary connection” (TCPC) or Fontan 
procedure after the French surgeon who described it in 1978 [27]. 
INCIDENCE 
The incidence of congenital heart disease in liveborn is reported to be 6.4 to 
11.1 per thousand [28-32]. The variation is mainly due to the definition of 
congenital heart disease and the detection rate. Postnatal detection rates 
generally increased in the 1990s, likely due to more advanced ultrasound 
technology [31]. Norway reported variations within the population with an 
increase of cardiac defects from 1994 to 2000 followed by a per-year decrease 
of 3.4% for severe cardiac defects noted from 2004 onward. There was an 
increasing practice of termination of pregnancy (ToP) when severe heart 
disease was diagnosed during this time, but the authors thought elimination of 
risk factors and a possible benefit of pre-conceptional folic acid 
supplementation were more important factors to explain the decreasing 
incidence [31]. HLHS is the cardiac lesion with the highest prenatal detection 
rate and in Sweden and many other countries there is a high termination rate 
when detected in utero. The incidences of HLHS before general prenatal 
screening, or in populations where the termination rate is low, are reported to 
be 8 to 27 per 100,000 live births, Table 1, page 14 [28, 30, 33, 34]. The 
incidence of univentricular hearts (UVH) in relation to an increasing prenatal 
detection and termination rate was investigated in Denmark where a significant 
decrease in incidence was reported from 2003. There was an increasing 
number of terminations from 2003 onward, with a termination rate of 85% for 
UVH in 2009 [35].  
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Table 1. Incidence of HLHS as reported in the literature. HLHS included cases 
with AS and AA as defined in the table. The incidence per 100,000 liveborn 
neonates was calculated by the author (AÖ) [28-31, 33, 34, 36-39].  
Author Year Geographical 
area 
Morphology N Study 
population 
Incidence per 
100,000 
 
Carlgren 1959 Sweden AA and AS 24 58,105 41 
Brownell 1976 Canada AA 64 - 25 
Samanek 1989 Bohemia AA and AS 24 91,823 26 
Samanek 1999 Bohemia AA and AS 172 816,569 21 
Hoffman 2004 California, US HLHS - - 23 (28) 
McBride 2005 Texas, US HLHS 166 1,077,574 15 (13–18) 
Reller 2008 Atlanta, US HLHS VSD 91 398,140 23 
Moons 2009 Belgium HLHS 10 111,225 9 
Leirgul 2014 Norway HLHS 154 943,387 16 
Qu 2016 China HLHS - - 8 (6–10) 
Abbreviations: AA, aortic atresia, AS, aortic stenosis, HLHS, hypoplastic left 
heart syndrome, VSD, ventricular septal defect 
INCIDENCE IN RELATION TO GENDER  
The distribution between the genders in the general population is a slight male 
excess with a ratio of 1.04–1.06:1 for male versus female gender. For certain 
cardiac defects such as transpositions of the great arteries, coarctation of the 
aorta and HLHS, the male excess is higher than in the general population [40]. 
A multicenter study, including registry data from the US, Europe and 
Australia, reported 2,062 cases of HLHS, of which 1,297 were male, resulting 
in a ratio of 1.7:1 [40]. A study from the Texas Birth Defects Registry of the 
years 1999–2001 reported 166 cases of HLHS, 110 of them male, resulting in 
a male-to-female ratio of 2:1 [37, 41]. In the Bohemian population, the ratio 
was 2.25:1 [42].  
PRENATAL DETECTION RATE AND OUTCOME OF PREGNANCY 
The increase in the prenatal detection of cardiac malformations after 
implementation of a general screening program was reported from the County 
of Stockholm. The detection rate of significant cardiac malformations (cardiac 
surgery before 1 year of age) was 7.1% in 1997 compared to 41.0% in 2004 
 15 
[43]. A prenatal diagnosis of HLHS gives the parents option of terminating the 
pregnancy in countries where this is legal. When the parental wish is to 
continue the pregnancy, the prenatal diagnosis allows for a safe in-utero 
transfer to a cardiac surgical center. 
The proportion of termination of pregnancy (ToP) after a prenatal diagnosis 
of HLHS has been reported from Denmark, Sweden and Australia to be 60–
85%  [35, 43, 44] . The proportion of fetuses with HLHS that will be liveborn 
depends on the prenatal detection and termination rate. A significant regional 
difference in prenatal detection and termination rates for single ventricle 
lesions in 1996-2006 was reported by the Swedish National Board of Health 
and Welfare. They noted a termination rate of 45% in the region with the 
highest detection rate and 5% in the region with the lowest detection rate. The 
difference in termination rates was mainly explained by the variation in 
prenatal detection rate [45]. Improvements of the population based screening 
program have resulted in more similar care in all regions but differences still 
exist and there are no coherent guidelines in Sweden for what cardiac views to 
include at the routine ultrasound screening at 18-19 weeks of gestation [46].  
In continuing pregnancies, a prenatal diagnosis allows for centralized 
delivery This should potentially facilitate optimal care of the neonate from 
birth. A population-based study from Texas found that prenatal diagnosis did 
reduce neonatal mortality if mothers living far from a cardiac surgical center 
delivered closer to one [47]. In a systematic review from 2016, Thakur et al. 
evaluated the preoperative mortality in 609 neonates with HLHS, 228 with a 
prenatal diagnosis and 381 with postnatal diagnosis. There was no statistical 
difference in preoperative or post-stage I mortality between the groups, but 
neonates with a prenatal diagnosis were hemodynamically more stable [48]. In 
Finland, a country with long distances to tertiary care, centralized delivery 
resulted in improved postnatal right ventricular function and less metabolic 
acidosis and less end-organ failure in neonates with a prenatal diagnosis of 
HLHS [49].  
OUTCOME 
Implementation of surgical programs for palliation of HLHS in relation 
to improved results and identification of risk factors in the early surgical 
era 
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A few decades ago, the only option for children born with HLHS was terminal 
supportive care (comfort care) until a staged palliative surgical method was 
suggested by Norwood in 1981 [50, 51] and introduced in Sweden in 1993. 
The pioneering work of developing the method was mainly done at institutions 
in the US [50, 52, 53]. In Europe, Birmingham (UK) was one of the first centers 
to publish the results of a prospective audit in 1993. The general trend in the 
1990s was toward improved surgical survival due to continued experience with 
both operative and postoperative management [6, 52, 53].The causes of death 
after the modified Norwood procedure was studied in 122 postmortems, 
showing impairment of coronary perfusion, excessive pulmonary blood flow, 
obstruction of pulmonary blood flow, neo-aortic obstruction and right 
ventricular failure as the leading causes [54]. When 10 potential risk factors 
for first-stage mortality were analyzed, only cardiopulmonary bypass and 
circulatory arrest times were predictive of total survival, including late deaths 
[55]. Early experience with the Norwood procedure in Scandinavia was 
reported from Denmark in 1997, where a surgical program was initiated in 
April 1993. As of June 1996, 31 patients had been referred. Twelve of them 
were not considered for surgery, either because of parental wishes or because 
of hemodynamic instability. Nineteen patients underwent a Norwood 
procedure. There were 13 hospital survivors, of which 8 (42%) were alive at a 
mean follow-up time of 19 months. In Norway, health authorities initiated a 
program in 1987 where they decided to pay all expenses for transportation, 
examination, and treatment with staged palliation in the US or Europe. The 
majority of patients were referred to Philadelphia from 1987 through 1998. At 
a midterm follow-up, 12 of 31 (39%) patients who had undergone at least one 
palliative procedure abroad were alive [56].  
Modification of the Norwood procedure with introduction of the right-ventricle-
to-pulmonary-artery-shunt (Sano shunt) 
In 2002, Sano and colleagues at the Okoyama University Hospital in Japan 
presented a modification to the Norwood procedure. They employed a shunt 
from the right ventricle directly to the pulmonary arteries, and they reported a 
clear difference in postoperative hemodynamics between the direct shunt and 
the more traditional systemic-to-pulmonary arterial shunts (BT and modified 
BT shunt). They suggested an optimal size for the shunt of 5 mm in patients 
weighing more than 2.0 kg and 4 mm for smaller patients. They thought the 
direct shunt would be particularly beneficial for small neonates [57]. A 
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comparison of shunt types was performed in a randomized trial conducted in 
15 North American centers, the single-ventricle reconstruction trial (SVR trial) 
[58]. The primary outcomes were death or cardiac transplantation 12 months 
after randomization. Transplantation-free survival was higher with the Sano 
shunt than with the modified BT shunt (74% vs. 64%, p=0.01). At high volume 
centers, the advantage of a Sano shunt was negated [58].  
Intermediate-term transplantation-free survival after Norwood surgery and 
interaction with shunt type 
An intermediate-term evaluation of mortality and transplantation in relation to 
risk factors and their interaction with shunt type in the same cohort as above 
was presented in 2012. The cohort included 549 subjects with a mean follow-
up of transplantation-free survivals of 2.7 +/- 0.9 years, with a maximum of 
4.4 years. Risk factors were categorized as early-phase factors versus constant-
phase factors, and as intrinsic, non-modifiable, or modifiable. Modifiable 
factors were factors that might be subject to practice variations. Early-phase 
factors associated with death included lower socioeconomic status, obstructed 
pulmonary venous return, smaller ascending aorta and anatomic subtype, 
AA/MS having higher risk compared to AA/MA [59, 60]. Constant phase 
factors associated with death included genetic syndrome and lower gestational 
age. The Sano shunt was associated with better survival rate in the 51% who 
were full term with AA. The modified BT shunt was better among the 4% who 
were preterm (gestational age less than 37 weeks) with a patent aortic valve. 
Transplantation was used in 3% of subjects following the Norwood procedure. 
The authors pointed out socioeconomic status and gestational age as 
potentially modifiable. Although early delivery is sometimes inevitable, they 
emphasized the increased risk of earlier elective delivery. They concluded that 
provision of services to compensate for the challenges associated with low 
socioeconomic status could positively impact outcome [60]. 
Interstage mortality between stages I and II 
After discharge from the hospital, there is a continued significant risk of death 
before stage II surgery. The interstage mortality was reported to be 12% in a 
multicenter study in North America [61]. Improved interstage survival has 
been reported by institutions practicing a home monitoring program with daily 
monitoring of oxygen saturation and weight [62, 63]. To prevent shunt 
occlusion caused by the formation of a thrombus, anticoagulation therapy is 
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widely practiced. Guidelines for antithrombotic therapy in neonates and 
children, published in 2008, recommend intraoperative unfractioned heparin 
followed by aspirin (1–5 mg/kg/d) or no further antithrombotic therapy for 
patients undergoing surgery with a modified BT shunt. The recommended 
doses of aspirin in neonates and children are empirical [64]. Aspirin 
(acetylsalicylic acid, ASA) inhibits platelet aggregation by inhibiting 
cyclooxygenase irreversibility. A drug that could give an additive effect on 
platelet aggregation by inhibiting ADP in platelets, Clopidogrel, was studied 
in a randomized controlled study in patients with BT- shunts [65]. The primary 
end point was death or heart transplantation, shunt thrombosis, or performance 
of a cardiac procedure due to an event considered to be thrombotic in nature. 
There was no significant difference in risk in any of the primary end points to 
occur between the treated group (19%) and the placebo group (21%). This was 
true also in subgroups defined by shunt type. There is lack of a “gold standard” 
in thrombo-prophylactic strategies after Norwood surgery [66]. 
Optimal timing of the second stage in the palliative surgical treatment of HLHS 
The optimal timing of stage II surgery has been the subject of several 
investigations. A recent study investigated the optimal timing of stage II 
surgery by analyzing the cohort of the Pediatric Heart Network Single 
Ventricle Reconstruction Trial Dataset of 547 infants with HLHS that 
underwent Norwood surgery. The optimal timing of stage II was determined 
by plotting calculated three-year transplantation-free survival versus the 
Norwood to stage II survival. Calculated transplantation-free survival at three 
years was stable at 68 +/- 7% during an inter-stage interval of three to six 
months. Calculated survival decreased rapidly when stage II was performed 
before three months and then again gradually after six months. Three-year 
survival decreased in patients defined as “high-risk,” with a transplantation-
free survival of less than 50%. An early stage II procedure did not rescue ill 
patients from poor outcome, and the authors questioned such a strategy. 
Optimal timing of stage II surgery did not differ between patients with 
modified BT shunts or right-ventricle-to-pulmonary-artery shunts. The authors 
pointed out the importance of a formal clinical protocol to ensure that operative 
planning for stage II in infants with low or average risk factors was put in place 
at discharge after Norwood surgery [67].  
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Outcome and risk factors for death after stage II surgery 
Carlo et al. studied interstage attrition, defined as death or cardiac transplant 
more than 30 days after bidirectional Glenn (BDG) and before the Fontan 
procedure. They concluded that moderate or severe tricuspid valve 
regurgitation and low weight z-score at the time of BDG were important risk 
factors for subsequent interstage attrition [68]. Alsoufi et al. reported the 
outcome after BCPC for a number of single-ventricle malformations, including 
HLHS. Survival rates were analyzed and stratified by underlying condition, 
showing the lowest 5-year survival (63%) in the HLHS group. In addition to 
previously mentioned risk factors, AV-valve regurgitation and lower weight, 
the authors pointed out a significantly higher risk of death in the group of 
single-ventricle patients with preoperative pulmonary vascular resistance 
index above 3 WU/m2 [69].  
Outcome after stage III surgery 
Early experience using the Fontan procedure in HLHS patients was reported 
by Farrell in 1992 to have comparable survival rates as patients with other 
complex cardiac lesions [70]. More recent studies report a higher risk of major 
events in the HLHS population after Fontan completion compared to patients 
with other underlying conditions. In a multicenter study, including centers in 
North America, the UK and Australia, the outcome of patients with HLHS 
reaching adulthood after Fontan palliation was reported. Five hundred forty-
three patients underwent the Norwood procedure before 1996 with a total pre-
Fontan mortality of 71% (n=383). Post-Fontan mortality was 5%. Fifty-nine 
patients reached adulthood (≥ 18 years), of which 60% were in functional class 
I (NYHA I). The baseline aerobic capacity was < 85% of the prediction in 98% 
of the patients. There was a high prevalence of major events reported over the 
first years of follow-up in adulthood. This observation showed that the cohort 
of young adults with HLHS differed from other patients with Fontan 
circulation, where the complications were common over decades rather than 
within a few years of adulthood. The number of patients in the study was 
considered too small to evaluate specific risk factors of events [71]. 
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SURVIVAL AFTER NORWOOD SURGERY 
The overall survival after Norwood surgery has been reported by several 
authors. Table 2 shows a summary of recent reports.  
 
Table 2. The results of earlier studies reporting survival. The included studies 
in the table are others than mentioned in the above sub-chapters. The 
measurements of survival were not uniform and are explained for each study 
in the “Survival” column. N represents the number of patients included in each 
study. 1 The survival probability was estimated from graphically depicted K-M 
curves. [72-78].  
Author Year Study 
period 
Geographical 
area 
Inclusion 
criteria 
N Survival 
Graham 2010 2000–
2005 
South 
Carolina, US 
Norwood 
procedure 
(HLHS and non-
HLHS) 
76 63–78% cumulative 
survival at 6 years 
Rychik 2010 2004–
2009 
Philadelphia, 
US 
Infant born with 
HLHS, standard 
and high risk, 
prenatal 
diagnosis 
185 Overall Norwood 
operative survival 
of 83.8%. 
Menon 2012 1995–
2010 
The state of 
Utah, US 
Infant born with 
HLHS 
245 33% 
transplantation-free 
survival rate at 14 
years 
Hansen 2012 1996–
2010 
Kiel, Germany Norwood 
procedure HLHS 
212 68% 
transplantation-free 
survival probability 
at 10 years1  
New-
burger 
2014 2005– Multicenter, 
US 
Norwood 
procedure 
(HLHS and non-
HLHS) 
342 60–64% 
transplantation-free 
survival at 5-years 
Ber-
oukhim 
2015 1995–
2008 
Boston, US Infant born with 
HLHS, standard 
risk, prenatal 
diagnosis 
150 72% 
transplantation-free 
survival probability 
at 10 years1  
Orr 2015 2006–
2011 
New South 
Wales, 
Australia 
Norwood 
procedure HLHS 
30 67% overall 
survival at 12 
months 
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ETHICAL CONSIDERATIONS  
Intention-to-treat, comfort care or termination of pregnancy (ToP) 
The management of fetuses and neonates with HLHS is a medical, surgical and 
ethical challenge. In the past, when there was no treatment available, mortality 
was 100% in the neonatal period. The introduction of Norwood surgery 
changed this perspective, and today survival probability is approximately 75% 
at 10 years in our country. Despite the improved survival there is still a 
considerable risk for death and there is co-morbidity and decreased aerobic 
capacity. The neurocognitive development is a raising concern [79]. These 
factors together are challenging and they are likely the main reasons why 
parents chose ToP after prenatal diagnosis or may refrain from treatment of 
liveborn neonates when ToP is not an option. The decision to terminate a 
pregnancy or to refrain from active treatment is obviously emotionally and 
ethically extremely stressful. The psychological consequences of ToP for fetal 
abnormalities are well described [80-82].  
The dilemmas faced in the decision-making process after a fetal or postnatal 
diagnosis of HLHS are medical, legal, financial, socioeconomic, personal, and 
ethical. The parents of a fetus or neonate with HLHS have to consider the 
potential suffering their child may endure over a lifetime, while at the same 
time considering that survival is superior to certain death [83]. The term 
“comfort care” has been used to describe the care of a neonate for whom a 
decision has been made to refrain from surgery.  
The choice to opt for ToP, comfort care or active treatment should be the 
parents’ alone, which is possible only after objective and detailed information 
given by initiated health care professionals. In some countries, legal 
jurisdiction limits the options, while medical or financial limitations are 
present in others. The awareness that the underlying condition of HLHS is 
severe and the treatment is extensive and expensive and carries high risks and 
also is a burden on the family is acknowledged. Societies where the prenatal 
detection rate and/or the termination rate is low, tend to favor comfort care as 
an alternative option to active treatment. There is recent data from Chicago 
(US) showing that one-third of infants with HLHS did not undergo surgical 
intervention [84]. A study from South Carolina, US reports that even though 
most professional caregivers would favor surgery, they believe that parents 
should have the option to choose comfort care [85]. The option to terminate 
the pregnancy is well accepted in many countries while it is illegal in others. 
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The ethical issues are similar for ToP and comfort care, except that comfort 
care means exposing the pregnant woman for the additional risk of delivering 
at full term.  
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FETAL AORTIC STENOSIS 
DEFINITION 
Aortic stenosis (AS) in fetal life is an echocardiographic diagnosis based on 
the morphology and function of the aortic valve. It is commonly seen in 
conjunction with additional left-sided lesions such as mitral valve anomalies 
and coarctation. In the presence of fetal AS, the left ventricle can be 
hypoplastic, of normal size, or dilated. The left ventricular function can be 
normal or decreased. There can be pathological changes to the myocardium 
and endocardium of the left ventricle known as endocardial fibroelastosis 
(EFE).  
INCIDENCE  
The Baltimore–Washington Infant Study reported aortic stenosis as accounting 
for 2.9% of all cases of congenital heart defects in liveborn neonates (1981–
1989). The incidence of aortic valve stenosis was 12.8 per 100,000 when 
diagnosed up to one year of age in a study by McBride [37]. The incidence of 
fetal aortic stenosis is not known and relies on a prenatal detection rate that is 
low for this condition [86]. In a retrospective report from London, 31 cases 
were identified during a 10-year period including 19,006 exams of pregnant 
women referred for specialized fetal echocardiography [87]. That would result 
in approximately three patients per year if the institution handles 1,900 yearly 
fetal echocardiograms on a tertiary level, (Gothenburg, 400 per year).  
NATURAL HISTORY 
Due to the low prenatal detection rate, previous reports of natural history in 
fetal AS involve few cases. In 1997, Simpson and Sharland reported 27 
consecutive cases. Gestational age at diagnosis was 18–35 weeks (median 22 
weeks). All except 2 had depressed left ventricular function at diagnosis. Left 
ventricular end-diastolic volume, function, and the aortic root diameter were 
monitored during pregnancy. Out of 9 cases in continuing pregnancies without 
fetal intervention (one case had a fetal intervention), 6 had a biventricular (BV) 
and 3 a univentricular (UV) outcome. At follow-up, 4 patients with BV 
outcome and one with UV circulation were alive. The authors observed that 
there frequently was a failure of growth of the left ventricle in the fetuses with 
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prenatally detected aortic stenosis. The predictive factors of UV outcome 
suggested were LV end-diastolic volume, ejection fraction and aortic root size 
[88]. The prenatal detection rate of critical AS in neonates that survive to 
hospital discharge with BV circulation is 5–9% while the prenatal detection 
rate for HLHS at the same institution is 60–100% [86]. Unlike other cardiac 
malformations, there has been no improvement in prenatal detection rate over 
time. In a report by Freud, 117 neonates with critical AS and BV outcome were 
studied. Ten had a prenatal diagnosis, 5 of them were diagnosed in mid-
gestation (5 were detected later) and had trivial to mild flow acceleration across 
the aortic valve, which was thickened and/or dysplastic and there was no other 
sign of depressed LV function. Left ventricular dysfunction developed by a 
median of 35 gestational weeks (28–35 weeks) in these patients, when signs of 
left-sided elevated filling pressures also became evident. There was a 
downward trend in z-score measurements of the aortic valve and mitral valve 
during pregnancy; however, it was not statistically significant [86].  
PATHOPHYSIOLOGY 
A significant obstruction of the aortic valve alters the development of the left 
ventricle. In the presence of an increased end-systolic pressure, a mature 
myocardium becomes hypertrophied and by doing so the contractile force 
increases while the wall stress decreases according to Laplace law [89-91].  
 
Laplace law ;  𝑤𝑎𝑙𝑙 𝑠𝑡𝑟𝑒𝑠𝑠 =
𝑃×𝑟
2× 𝑤𝑎𝑙𝑙 𝑡ℎ𝑖𝑐𝑘𝑛𝑒𝑠𝑠
 
P=Pressure, r= radius 
 
The fetal myocardium is programmed for cell hyperplasia rather than 
hypertrophy and has poor mechanisms to compensate for increased pressure 
load [92]. In cases with preserved diastolic function, the filling of the left 
ventricle is normal. The result in cases with obstruction of the aortic valve with 
preserved diastolic function is usually dilatation of the left ventricle. When the 
ventricle dilates, the afterload increases even more and the ventricle cannot 
preserve its systolic or diastolic function. A vicious circle can begin with 
ischemia, development of EFE, diastolic dysfunction, and halted growth of the 
left ventricle. Not all cases of AS in fetal life progress to HLHS. The left 
ventricle can handle mild to moderate obstruction, and most cases of critical 
aortic stenosis at birth will go unnoticed during fetal life [86].  
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HEMODYNAMICS 
When there is increased pressure in the ventricle, atrial pressure rises as well. 
The normal fetal shunting from right to left across the interatrial septum 
gradually decreases, and in severe cases the flow direction through the foramen 
ovale (FO) changes to bidirectional or even left-to-right. The decreased filling 
of the left ventricle in combination with the obstruction of the aortic valve will 
result in decreased stroke volumes. The cardiac output produced by the left 
side of the fetal heart will not sufficiently supply the head and neck vessels and 
their end organs with adequate pressure and flow. In this situation, there will 
be compensatory flow supported by the right side of the heart through 
retrograde flow in the aortic arch from the arterial duct [93]. In unfortunate 
cases, the FO closes during pregnancy. Pulmonary venous return depends on 
low left atrial pressure during ventricular systole and early diastole. With 
restriction at the atrial level the flow pattern in pulmonary veins becomes 
reversed during atrial systole, A-wave reversal. In severe cases bidirectional 
flow develops, also known to as “to-and fro flow”. High pressure in the 
pulmonary veins is a risk factor for developing lymphangiectasia of the fetal 
lungs [94, 95]. This condition is associated with postnatal pulmonary 
hypertension and high mortality [96].  
Hydrops 
Hydrops is a complex fetal process with several different causes. When 
hydrops is present in cases of congenital heart malformation, the reason is 
increased pressure in the right atrium, usually due to severe tricuspid 
regurgitation. Hydrops is rare in conjunction with left-sided obstructive 
lesions, but can be seen when the right ventricle is unable to handle the 
increased volume and pressure load [97].  
FETAL VALVULOPLASTY 
The rationale behind a fetal cardiac intervention on a stenotic aortic valve (FV), 
is to relieve the left ventricular outflow tract obstruction to enable continued 
growth of the left-sided cardiac structures in order to aim for a biventricular 
(BV) circulation at birth. A second indication is to enhance the chances of fetal 
survival when there are signs of cardiac failure (hydrops) in combination with 
left-sided obstructions with or without a restrictive atrial communication. The 
optimal timing of an intervention when the aim is a BV circulation is not 
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known, but it is likely that an early intervention is preferred to achieve the best 
effect. The technical aspects of intervening in small hearts and the fact that 
many cases are detected late in midgestation limits the possibilities of 
intervening earlier than at about 20 weeks. Most interventions are performed 
at midgestation between 24-26 gestational weeks (range 19-34 weeks) [98-
100]. How to perform a fetal cardiac intervention includes fetal as well as 
maternal considerations. In most centers, the team performing the fetal cardiac 
intervention includes maternal and fetal medicine specialists, fetal 
cardiologists, and cardiac interventionists. Detailed procedural and technical 
information on how a fetal cardiac intervention is performed has been 
published [100-108]. The reports include information on maternal and fetal 
preparations, resuscitation drugs, techniques for reaching and dilating the 
aortic valve, needle and balloon sizes, and fetal and maternal complications.  
Procedural information 
The fetal heart can be reached by a small laparotomy in the maternal abdomen 
or percutaneously, using a needle to traverse the different maternal and fetal 
layers. In the current era, a percutaneous approach is used [101, 109, 110]. 
Essential to gain access to the fetus is a favorable fetal position, which can be 
attained through positioning of the mother or by gentle manipulation of the 
fetus [101]. The direction of the cannula through the different layers of the 
maternal abdomen and the fetus is guided by ultrasound. The cannula is 
directed towards the fetal aortic valve, and when in position, the cardiac 
interventionist inserts a guidewire with a balloon. The balloon is inflated across 
the aortic valve, and after repeated inflations the cannula, the guidewire, and 
the balloon are removed from the patient [100, 101]. Technical success is 
achieved when the aortic valve is crossed, the balloon is inflated, and color 
Doppler ultrasonography show increased flow across the aortic valve and/or 
new aortic regurgitation [100]. Fetal complications are common, most 
complications occur during or shortly after the intervention. Cases of fetal 
demise in close relation to the intervention has been reported [98, 100, 101]. 
Major maternal adverse events are rare [104]. The women are mostly  
discharged from the hospital the same day, or when general anesthesia is given 
they stay overnight [101] [104]. The fetal cardiac function is assessed by 
ultrasound the day after the procedure. Initiation of digoxin therapy after 
successful intrauterine valvuloplasties is practiced at some institutions [100] 
[104] .  
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CHANGES IN PATHOPHYSIOLOGY AND HEMODYNAMICS FOLLOWING 
FETAL VALVULOPLASTY 
The aim of performing a fetal intervention with balloon dilation 
(valvuloplasty) of the aortic valve is to relieve the obstruction at the aortic 
valve level, thereby restoring normal pressure and flow through the left 
ventricle. Previous reports show that hemodynamics and growth can be 
restored after an intervention but there are no observations so far suggesting 
that there will be a catch-up of left heart growth [98, 111, 112]. Changes in 
hemodynamics can be followed with fetal echocardiography, a method that 
will be discussed more in the following section.  
FETAL ECHOCARDIOGRAPHY AS PREDICTOR OF OUTCOME 
Association between fetal echocardiographic measurements and outcome has 
been described for a number of fetal cardiac conditions [113-115] including 
fetal AS [98, 116]. Mäkikallio et al reported that UV outcome in fetal AS with 
normal sized left ventricle could be predicted before 30 weeks of gestation by 
combining functional data of depressed left ventricular function, retrograde 
flow in the transverse aortic arch, left-to-right flow at the atrial level and 
monophasic mitral Doppler inflow pattern [116].  
The described hemodynamic changes associated with UV outcome were 
tested by Hunter et al [87]. Their result was comparable with Mäkikallio, 
except for FO flow left to right that showed poor sensitivity.  
The potential for BV circulation and the potential for a technically 
successful intervention in hearts fulfilling criteria for UV outcome is given by 
the size of the left ventricle and signs of some preserved function measured by 
pressure gradients across the aortic forward- or mitral backward flow [98].  
The previous and current selection criteria for fetal aortic valvuloplasty as 
practiced in Boston include three main criteria. The first is a dominant cardiac 
anomaly of valvar AS, the second is criteria for evolving HLHS [116] and the 
third is potential for a technically successful procedure and BV outcome 
postnatally [98]. The criteria for evolving HLHS was modified compared to 
Mäkikallio by adding bidirectional flow in pulmonary veins.  
The “early” or “previous criteria” used to select cases with BV potential 
were LV long axis z-score ≥ minus 2, depressed LV function but generating at 
least a 10 mmHg pressure gradient across the aortic valve or 15 mmHg mitral 
  28 
regurgitation (MR) jet gradient and a mitral valve z-score > minus 3. The 
criteria were modified based on the findings that interventions were performed 
in too small hearts with little potential of BV outcome.  
The modified criteria stated that the diagnosis should be unequivocal AS 
(versus AA), LV long axis z-score > minus 2 and a threshold score ≥ 4. The 
threshold score was designated to give one point for each of five variables; LV 
long axis z-score > 0, LV short axis z-score > 0, aortic annulus z-score > minus 
3.5, MV annulus z-score > minus 2 and a pressure gradient of ≥ 20 mmHg, 
MR or AS.  
The outcome before and after modification of criteria showed an increased 
number of cases with BV circulation after implementation of the revised 
criteria [8].  
The experience from Linz presented by Arzt et al. [100] was in agreement 
with the results from Boston. The successful cases had a mean LV long-axis 
z-score well above zero. The early results from Linz resulted in a modification 
of their criteria as well. The criteria for fetal AV valvuloplasty after 2014 in 
Linz are fetal AS as the dominant lesion with retrograde flow in the aortic arch, 
left-to right shunt across the FO, LV long-axis z-score > minus 2 and a LV:RV 
ratio > 0.8 [100].  
REPEATABILITY (INTRA-OBSERVER VARIABILITY) AND 
REPRODUCIBILITY (INTER-OBSERVER VARIABILITY) OF FETAL 
ECHOCARDIOGRAPHIC MEASUREMENTS  
Echocardiography is a commonly available tool using ultrasound and the 
Doppler effect to perform a noninvasive test in patients with known or 
suspected cardiac disease. The method provides evaluation of cardiac 
structure, function and hemodynamics in fetuses, neonates, children and adults. 
Two-dimensional echocardiography is the foundation of an echocardiographic 
exam demonstrating cardiac structure and function. Motion of cardiac 
structures can also be displayed with high frame rate in a distance- time graph 
with high temporal resolution; M-mode. Doppler colour flow imaging 
visualizes blood flow direction and relative velocity. Spectral Doppler displays 
the blood flow measurements graphically, showing flow velocities recorded 
over time.  
Fetal echocardiography was introduced for research purposes in the early 
1970s using basic M-mode to image fetal cardiac motion. In the 1980s, basic 
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two-dimensional ultrasound was able to delineate cardiac structures, function, 
and rhythm [117], creating a use for the method in clinical practice. Today, 
fetal echocardiography has a high degree of accuracy in diagnosing fetal 
cardiac malformations and arrhythmias in the hands of specialized fetal 
cardiologists and obstetricians [118]. Although well developed in clinical 
practice, little is reported on the repeatability and reproducibility of fetal 
echocardiographic results in research. In 2002, Simpson et al. reported 
repeatability of echocardiographic measurements in the human fetus. Thirty-
two different variables, including cross-sectional, M-mode, and spectral 
Doppler, were measured from videotape by two independent observers in 10 
normal fetuses at 23 (17–34) weeks. They concluded that the repeatability of 
most echocardiographic measurements in the fetus was poor. Inter-observer 
errors were consistently higher than intra-observer errors. Cross-sectional 
values and some of the spectral Doppler variables, specifically max velocity, 
performed better than M-mode measurements. The influence of small 
structures of the fetal heart was a source of potential errors. Color Doppler was 
not evaluated [119]. Studies on the validity of assessing fetal arrhythmias are 
more frequent [120], often including the correlation between Doppler flow 
echocardiography and AV time intervals [121].  
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PATIENTS AND METHODS 
STUDY DESIGN 
The studies included in this thesis were all considered to be epidemiological 
studies. Those in Papers II–V were observational, while the study in Paper I 
was experimental. All studies included an analytical part. Paper IV presented 
traditional epidemiology describing incidence of disease. The cohorts in 
Papers II–V were historical or nonconcurrent, for which data were collected 
retroactively. The study presented in Paper I included an intervention (home 
monitoring) that was initiated by the investigator. Patients included in Paper I 
were consecutively assigned to an intervention without a randomization 
process.  
Traditionally, epidemiology was only descriptive and aimed to study the 
distribution and determinants of health-related events in populations [122]. 
Modern epidemiology includes descriptive and analytical studies as 
illustrated in Figure 1. Descriptive epidemiology uses available data to 
describe how mortality and morbidity rates vary according to the 
characteristics of a given population (demographic variables). In the field of 
analytical epidemiology, studies are designed to allow the assessment of 
hypotheses that associate exposure factors with a health-related outcome [122]. 
The hypotheses can be assessed either by experimental or observational 
studies. In an experimental study, the researcher exposes the subject to an 
intervention in a randomized or non-randomized way.  
Observational studies are those in which a correlation between exposure 
and outcome is observed, but no intervention is introduced by the researcher. 
Studies that include individuals as observational units are cohort studies, case-
control studies, or cross-sectional studies, Figure 2. The cohort study is a 
longitudinal study also known as “prospective,” which refers to the basic 
concept of a cohort study—that the exposure is known before the outcome and 
that the cohort is followed over time.  
Data can be collected retroactively in a cohort study and the cohort will then 
be a “nonconcurrent” or “historical” cohort. The “nonconcurrent” or 
“historical” cohort is characterized by the investigators beginning the study at 
the end of the follow-up time. The main advantage of a concurrent cohort, or 
“truly prospective” study compared to a nonconcurrent study is that the 
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baseline exam, follow-up methods, and ascertainment of events are planned 
and implemented for the purpose of the study [122].  
Cohort studies are considered “the gold standard” of observational studies, 
while case-control and cross-sectional studies are justified primarily by the 
logistic ease of performing them.  
The epidemiological study design with the highest grade of evidence is the 
randomized controlled trial, a study design with the potential to reduce 
confounding and bias when performed under strictly controlled conditions.  
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Figure 1. Epidemiological studies can be experimental or observational. 
Experimental studies can include a randomized or a non-randomized 
assignment process. When an observational study includes an assessment of 
a hypothesis, for example a comparison between groups, the study is 
analytical.  
 
 
 
 
Figure 2. The analytical approach can be of a prospective nature, when 
exposure is known before the outcome (cohort study); of retrospective nature, 
when the outcome is known and exposure is investigated (case-control 
study); or a cross-sectional study where exposure and outcome are 
investigated at the same time.  
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STUDY POPULATIONS, EXPOSURES AND OUTCOMES  
The main components in an epidemiological study are the patients, the 
exposure variables, and the outcome. The correlation between exposure and 
outcome is observed and the difference between groups with different 
exposure can be analyzed. Subjects included in a study population or a cohort 
should share some health-related characteristics and be included at the same 
stage in a possible progression towards a health-related outcome. In a cohort 
study the exposure variables are factors present in the study population at 
inclusion. The outcome is the result of the exposure on the included subjects 
over time. Outcomes can be death, morbidity, change in blood pressure, or any 
other well-defined entity.  
Table A in the Appendix of this thesis shows the patient populations, 
cohorts, and subgroups of cohorts for all studies. Table B shows outcome, 
exposure and possible confounding and interactive factors in relation to the 
correlation between exposure and outcome for the cohorts studied in Papers II-
III. Table C shows the outcome, exposure, possible confounders, and potential 
modifiable factors for the cohorts studied in Papers IV and V.  
The study subjects in Paper I were patients with single-ventricle physiology 
and a shunt as the only source of pulmonary blood flow. They were included 
at the same stage (discharge from hospital after stage I) in a possible 
progression towards a health-related outcome (survival to stage II surgery). 
The exposure factor was home monitoring of saturation. Inclusion of study 
subjects was initiated by the physician on the ward before discharge after 
informed consent from the parents. The outcomes were queried retrospectively 
in medical records and compared to a historical cohort without home 
monitoring.  
The patients included in the cohort in Paper II were identified by fetal 
cardiologists in Europe. The inclusion criterion was fetal diagnosis of aortic 
stenosis. The studied outcomes reported by the submitting fetal cardiologists 
were pregnancy outcome, postnatal outcome, and outcome after first 
intervention. Pregnancy outcomes were ToP, spontaneous intrauterine death 
(sIUD), and live birth. The postnatal outcomes were intervention (surgery or 
catheter) or no intervention. Overall survival was estimated for all liveborn 
with intention-to-treat. For patients who underwent an intervention, 30-day 
mortality was observed. Changes in morphology and physiology during 
pregnancy were analyzed and related to the outcomes.  
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The patients constituting the cohorts in Paper III were identified in the same 
way as in Paper II, with the addition of a group that underwent fetal 
valvuloplasty (FV).  
The cohort in Paper IV consisted of all liveborn neonates with HLHS/AA 
born in Sweden from 1990–2010, identified through merged searches of 
national databases and local surgical and fetal databases. The subjects were 
included at birth and followed until death or first surgery. The outcome, 
surgery versus no surgery, was analyzed in relation to exposure factors. A 
hypothetical cohort consisting of all fetuses with HLHS/AA was also included. 
The cohort was identified by estimating the fetal incidence from the incidence 
of liveborn neonates with HLHS/AA before prenatal detection- and 
termination rate was significant. The outcomes of the hypothetical fetal cohort 
were ToP, live birth and surgery and live birth and no surgery.  
The same cohort as identified in Paper IV was studied in Paper V, but 
limited to cases that underwent surgery in 1993–2010. The outcome 
transplantation-free survival was analyzed in relation to multiple variables 
(exposure factors).   
CONDUCTING RESEARCH USING NATIONAL REGISTER DATA 
The great strength of conducting research based on national register data is the 
completeness of the data. Reporting is compulsory and few patients’ data are 
lacking or get lost, so the data are easy to follow up. The basis of research using 
Swedish national databases is the Swedish personal identity number, which is 
maintained by the Swedish Tax Agency for all individuals who have resided 
in Sweden since 1947. The most important use of the identity number in 
healthcare is to trace patients and their medical records. The number (YY-MM-
DD-ABCD) is unique for each individual and is a marker of age and gender 
[123]. In surveillance of healthcare (national databases), the number is used for 
vital statistics (date of birth, date of death), but it is also the identifier and the 
key variable when matching between different registers. The main register 
holder for national databases regarding healthcare is the National Board of 
Health and Welfare, while Statistics Sweden keeps track of the number of 
inhabitants. The surveillance of congenital malformations and chromosomal 
abnormalities in relation to ante-and perinatal factors was put in place after the 
Neurosedyne disaster [124]. The “Registry for surveillance of congenital 
malformations and chromosomal abnormalities” contains one part on maternal 
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and neonatal data (The Swedish Medical Birth Registry, MBR) and one part 
reporting congenital malformations and chromosomal abnormalities in fetuses 
where the pregnancy is aborted. In the latter, there are no personal identity 
numbers registered. The coverage was low in the “fetal” part of the registry 
during the study period covered in paper IV and V according to the registry 
holder and was therefore omitted for data collection (personal reference, The 
National Board of Health and Welfare, September 2012). A description of each 
register used as source of information for Paper IV and V follows below.  
 
▪ The Swedish Medical Birth Register (MBR) was 
established in 1973, with the purpose of compiling 
information on ante- and perinatal factors and their 
importance for the health of the mother and child. The 
register includes data on practically all deliveries in 
Sweden. It is compulsory for every healthcare provider to 
report to the register, and the information in it is collected 
from medical records from prenatal, delivery, and neonatal 
care. A content and quality summary is found on the 
website.[125]  
▪ The Swedish Cause of Death Register (CDS) is a complete 
register of all deaths in Sweden since 1952, listing cause 
and time of death. Cause of death is registered according 
to the diagnosis represented by the international version of 
ICD codes. A detailed description of CDS was recently 
published [126]. 
▪ The Swedish National Inpatient Register (IPR) was 
established in 1964. The register has complete national 
coverage since 1987. Currently, more than 99% of all 
somatic and psychiatric hospital discharges are registered. 
It is mandatory for all hospitals to deliver data to the IPR. 
Variables are divided into patient and medical data, data 
about the caregiver, and administrative data. An external 
review and validation of the Swedish National Inpatient 
Register was published in 2011 [127]. 
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The Swedish Database of Forensic Medicine, Rattsbase, is a register of 
unnatural deaths that occur outside of hospitals. Rattsbase includes the 
diagnosis and brief information about clinical details and circumstances of 
death in free text [128]. The Swedish Registry of Congenital Heart Disease, 
SWEDCON, started in 2009 with the aim of monitoring patients with 
congenital heart disease. It includes information on diagnosis, if there was a 
prenatal diagnosis, performed surgeries, catheter interventions, and inpatient 
care. All of Sweden’s vital statistics are maintained by Statistics Sweden and 
updated daily with new births, migrations, deaths, and changes in marital 
status.  
ETHICAL CONSIDERATIONS IN RESEARCH STUDIES 
There were several ethical considerations regarding the studies included in this 
thesis.  
In Paper I, infants were included as subjects in an experimental study. 
Informed consent was given by the legal caregivers. Lack of consent by the 
caregivers excluded the patient. The risks of participation in the study were 
potentially related to the increased burden of stress on the guardians and the 
risk of neglecting signs and symptoms of disease if the home monitoring was 
normal. The questionnaire that was sent out by mail could potentially breach 
confidentiality. The ethical considerations above were described in an ethical 
application and the study was approved by the Regional ethical review board 
in Gothenburg.  
The observational cohort studies of patients with HLHS/AA in Papers IV 
and V included data from several databases, and information from different 
sources were merged. The main risk ethical concern was loss of privacy. 
Precautions were taken to protect the subjects with a negligible risk of 
identifying individual patients. The personal identity number was known to the 
researchers only for patients who underwent the Norwood procedure; the 
remaining patients were totally anonymous. Information about the study was 
announced in the journal Hjärtebarnet, which reaches the majority of parents 
of children with congenital heart disease. Ethical permission to identify the 
cohort and to investigate exposure and outcome in the study population was 
applied for and granted by the Regional ethical review board in Gothenburg. 
The two studies on fetal aortic stenosis were conducted as multi-center 
studies in Europe with the principle investigator situated in London, UK. The 
 37 
potential risk was mainly connected to loss of privacy, but since no patient 
identification data were submitted to the study, this risk was considered to be 
very low. The ethics committee at the institution with which the principal 
investigator was affiliated advised that the study was an audit rather than 
research, so no ethical permission was needed.  
In epidemiological research studies population-based outcomes and 
consequences of health problems are studied. The same basic ethical principles 
apply to epidemiologic research as to all research in medicine and are regulated 
in the Declaration of Helsinki [129]. The general principles of the declaration 
bind the physician with the words “the health of my patient will be my first 
consideration” and “a physician shall act in the patient’s best interest when 
providing medical care”. The declaration regulates how to apply this in 
medical research through a number of principles listed below. The list is a 
shortened version of the complete declaration found on the World Medical 
Association website citing the ethical principles for medical research involving 
human subjects [130].   
 
1. Medical research involving human subjects may only be conducted if 
the benefit outweighs the risks (beneficence and non-maleficence). 
2. All vulnerable groups and individuals should receive specifically 
considered protection. 
3. The design and performance of each research study involving human 
subjects must be clearly described and justified in a research protocol.  
4. The research protocol must be submitted to a research ethics 
committee for consideration, comment, guidance, and approval before 
study begins.  
5. Every precaution must be taken to protect the privacy of research 
subjects and the confidentiality of their personal information.  
6. In medical research involving human subjects capable of giving 
informed consent, each potential subject must be adequately informed 
and thereafter give informed consent to participation. Special rules 
apply for incapable subjects and for studies using human material or 
data contained in biobanks.  
7. Researchers have a duty to make publicly available the results of their 
research on human subjects and are accountable for the completeness 
and accuracy of their reports.  
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The risk to the individual is potentially lower in an observational study 
compared to an experimental study. In an observational study, the main risk is 
the loss of privacy, while an experimental study poses potential medical risks 
for the individual. The risk of loss of privacy in observational studies is higher 
when data are collected and merged from more than one source. The risk 
should be estimated and balanced against the benefit of the research [131]. 
Experimental research is not permitted without informed and written consent 
by the study participants. Special rules apply when informed consent is 
impossible or difficult to obtain as it is in research involving children or 
fetuses. In the case of a child under 15 years of age, the legal guardian(s) can 
give informed consent. The child has the right to be informed according to their 
developmental stage and age.  
Research involving fetuses needs special consideration, since the subject 
itself has no voice. From a legal perspective, the pregnant woman can give 
informed consent. The lack of direct consent from children and fetuses should 
not preclude them from being subjects in research when results cannot be 
extrapolated from other age groups. As regards observational studies, 
researchers have discussed the risk of selection bias when informed consent is 
warranted [132]. 
 The general rule of informed consent in the Declaration of Helsinki has 
been modified to facilitate observational studies using existing data [133]. The 
Swedish Medical Ethics Board states that studies using information from 
existing databases (registries) or medical records normally do not require 
informed consent [134]. Information to involved individuals and/or 
populations about ongoing research projects should be given collectively 
through media, healthcare information sites, or at healthcare institutions.  
For projects involving merged searches and data related to individuals, 
ethical approval is necessary. The recommendations are that informed consent 
is not required as long as the privacy of each research subject is fully protected 
and the results are reported by group and not on the individual level. 
Ludvigsson discussed the need for special precautions in vulnerable groups; he 
concluded that almost all registry-based research will involve vulnerable 
individuals and found existing regulations sufficient to protect these subjects 
as well as those less vulnerable [131]. As a conclusion, our studies satisfied the 
ethical principles discussed here.   
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STATISTICAL METHODS 
STATISTICAL MEASUREMENTS  
The included studies applied a wide range of statistical methods used to 
describe similarities or differences between groups, to describe and analyze 
correlation between exposure and outcome, and to describe and analyze 
incidence.  
In testing hypotheses regarding differences or similarities between two 
groups, the Chi-squared or Fisher’s exact tests were used for dichotomous 
categorical data, the Mantel-Haenszel Chi-squared test for ordered categorical 
data, and the Mann Whitney U-test for continuous variables. All tests were 
two-tailed and conducted at an 0.05 significance level. Different regression 
models were used to measure correlations between exposures and outcomes. 
Linear regression analysis was used for continuous variables and logistic 
regression for continuous and categorical variables. Survival analyses were 
conducted using the Cox proportional hazard regression analysis, taking time-
to-event into account and presented as hazard ratios (HR). Survival probability 
was presented graphically using Kaplan-Meier curves.  
The result of the evaluation of the correlation between exposure and risk 
was presented as “risk” or the probability of an event on the cohort level. For 
example, the risk of an event was higher for female neonates in the cohort of 
neonates with HLHS/AA compared to male neonates at HR 2.25 (95% CI 
1.35–3.7), Paper V, Table 4. The cohort-level risk gives an indication of the 
risk to the individual, but is in many situations too general to have a predictive 
value in the individual case. The more risk factors identified, the more 
individualized information can be given. The statistical model in Paper V, 
Figure 6 is a predictive model showing the results of a multivariable Cox-
regression analysis including several exposure variables found to be important 
for outcome.  
Criteria for fetal intervention are likewise predictive models including more 
than one risk factor with the aim of predicting the outcome (intervention or no 
intervention) for the individual.  
The validity and reliability of predictive models can be tested for the 
population using the measurements sensitivity and specificity, and on the 
individual level as negative and positive predictive values. In this thesis, 
criteria for fetal intervention were evaluated comparing proportions, but not 
measuring sensitivity or specificity. The validity and reliability of home 
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monitoring as a method to predict shunt complications were evaluated in Paper 
I.  
MEASUREMENTS OF INCIDENCE  
The incidence of HLHS/AA in Sweden was calculated by dividing the 
number of liveborn neonates with the disease by the number of neonates born 
in the country each year. The incidence rate ratio (IRR) was the measurement 
used to describe the change in incidence over time. The crude IRR was 
estimated using the Joinpoint Regression Program, a statistical modeling 
technique that explains the relationship between two variables by means of a 
segmented linear regression [135]. Adjusted IRR was estimated from a 
generalized linear equation (GEE) model with Poisson distribution and log-
link function.  
REDUCING BIAS AND CONFOUNDING IN OBSERVATIONAL STUDIES 
USING PROPENSITY SCORE  
Confounding is the term used when one or more factors influence the exposure 
and the outcome, making it impossible to investigate the correlation between 
exposure and outcome without modifications. The term interaction is used to 
describe situations in which two or more risk factors modify each other’s effect 
with regard to outcome. Bias can be defined as a systematic error in the design 
of a study, in the form of selection bias, information bias, or a combination of 
both. Exposure factors, outcome, and potential interactions, and confounders 
present in Paper I–V are listed in Appendix Table B and C. When comparing 
treatment effects, an experimental randomized controlled trial (RCT) is the 
“gold standard”. The RCT study design is superior in handling confounding, 
but is sometimes difficult or even unethical to perform. Propensity score (PS) 
is a statistical method used to handle confounding in an observational study 
[136-138]. The method transforms the observational study into an imaginary 
RCT using data from the observational study. The basic concept of using PS is 
“if”. The statistical method gives an imaginary experimental study design to 
allow us to answer the following question: 
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- If cases were similar and if they were selected to treatment 
versus no treatment by chance what would the treatment 
effect be? 
In a randomized controlled trial, the probability of receiving treatment is ½ 
(0.5). Confounders will randomly be distributed between treated and non-
treated cases and confounders will be equally distributed. The outcomes can 
be evaluated with the knowledge that confounding factors are equally present 
in both groups they will not be the explanation for the observed outcome. In 
an observational study, confounders are rarely equally distributed. The 
assignment to treatment versus no treatment is not random which can disturb 
the evaluation of the causal effect aimed to study.  This bias can be adjusted 
for in the imaginary model by calculating a score of the probability of being 
treated for each case. This is the propensity score (PS), which is calculated by 
using logistic regression models. In these models, the predictors of assignment 
to treatment are the selected variables and the outcome is treatment or no 
treatment. This will give each case a probability score of receiving treatment. 
Through this method, confounders will be “balanced,” allowing the causal 
effect of treatment to be investigated. The propensity score is then used to 
match and analyze outcome after treatment versus no treatment (the average 
treatment effect). The hypothesis being statistically tested here is the null-
hypothesis, that there is no difference in outcome after treatment compared to 
no- treatment. When using PS, an assumption is made, called the “Stable Unit 
Treatment Value Assumption (SUTVA),” that patients in a study should not 
interfere with each other and there should be no variation in treatment.  
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Figure 5. The distribution of logit propensity score (0–1) for treated cases 
(orange) and not-treated cases (blue). The probability for treated cases of 
being treated is normally higher than for the untreated group and they tend 
to have higher logit propensity scores. 
 
Figure 6. Cases with propensity scores within the overlapping range can be 
included in the analysis. When cases without overlap are deleted, propensity 
scores can be recalculated, a trimming process that can be iterated several 
times to improve balance. The balance of confounders within the selected 
cases is checked using the standardized mean difference. To improve the 
balance in the data and achieve a “better” standardized mean difference that 
is as close to zero as possible, you can apply inverse probability of treatment 
weighting (IPTW). This statistical method will “boost” the controls (if they 
are few) and make them stronger in comparison to the cases.  
 
In conclusion, the use of propensity score as statistical method in Paper III 
allowed us to reduce bias when comparing the natural history cohort and the 
FV cohort. 
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RESULTS 
The main results for each paper are listed below.  
 
I. There was a possible benefit from home monitoring of oxygen 
saturation on the individual level. There was no observed 
difference when the result was compared with a historical cohort. 
The method was well-tolerated by parents.  
II. The cohort of subjects with fetal AS demonstrated a spectrum of 
disease from mild to evolving HLHS. Cases that evolved into 
HLHS had a statistically significant lower z-score for the mitral 
valve diameter at the initial exam and a decreased growth velocity 
of the left ventricle and mitral valve during pregnancy. There was 
no significant correlation between physiological measurements 
and outcome. Cases fulfilling criteria for UV outcome had BV 
outcome in 33% of the cases while cases fulfilling criteria for UV 
outcome and BV potential had a BV outcome in 42 % of the cases.  
III. There was improved fetal hemodynamics and preserved left heart 
growth after FV compared to NH. There was no effect of FV on 
BV outcome, but survival was improved for propensity score 
matched cases after FV regardless of circulation.  
IV. The average incidence of HLHS/AA was 11.6 per 100,000 
liveborn in Sweden. There was an observed yearly decrease in 
incidence. The total number of patients born during the surgical 
era was 208, of whom 121 (58%) underwent surgery. The factors 
correlated to whether or not surgery was performed were birth 
period, birth location, prenatal diagnosis, and gestational age ≤ 37 
weeks. 
V. The result showed a transplantation-free survival of 51% in the 
entire cohort of patients with HLHS/AA who underwent the 
Norwood procedure in 1993–2010 in Sweden. Survival 
probability improved between the early and late birth periods and 
was 63% at 10 years for those born during the late birth period. 
Female gender was a risk factor for death. For male patients, there 
was an increased risk of death when there was a low birth weight 
in relation to gestational age.  
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SURVIVAL PAPERS I - V  
Survival was the outcome in all the included papers. The short-term survival 
after first intervention (catheter or surgical) was investigated and described as 
30-day mortality or interstage mortality. The definition of interstage mortality 
was death after discharge from hospital, Paper I, and alternatively referred to 
as the time period following after 30 days after intervention before next 
surgical stage in Paper V. The different definitions used were due to the aims 
of the studies and the quality of the data. The date of discharge from hospital 
was less reliable for the HLHS/AA cohort, while 30 days after surgery was 
certain. A comparison of survival between the cohorts in Paper I-V is 
presented in Table 3.  
 
Table 3. A comparison of survival of the cohorts presented in Paper I-V. 
Inclusion criteria SV and shunt FAS NH FAS FV HLHS/AA 
Paper  I II II III III V 
Circulatory outcome UV UV BV UV BV UV 
Number of cases  28 29 44 12 19 612 
30-day mortality (n)(%) . 8 (28%) 3 (7%) . . 7 (11%) 
Interstage mortality (n)(%) 4 (14%) 1 of 29 . . . 5 (8%) 
1-year survival . 57%3 78%3 . . 75%3 
5-year survival . 55%3 76%3 80%1,3 70%1,3 67%3 
Abbreviations: SV = single ventricle; FAS = fetal aortic stenosis; NH = 
natural history; FV = fetal valvuloplasty; HLHS = hypoplastic left heart 
syndrome; UV = univentricular circulation; BV = biventricular circulation. 
Indices: 1 Survival for liveborn neonates. There was a 10% procedure-
related loss in the fetal intervention groups, not included. 2 Patients born in 
2001–2010. 3Kaplan-Meier analysis of transplantation-free survival 
probability. 
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DISCUSSION 
The aim of the first study was to evaluate the possible effects of home 
monitoring of oxygen saturation on survival. There were individuals with a 
possible benefit from home monitoring, but no effect was observed on the 
cohort level. The clinical experience was optimistic and there was a general 
agreement to continue with home monitoring of oxygen saturation after the 
study ended. An observed increase of shunt complications was the reason to 
initiate the study and even though the effect could not be statistically proven 
the experience from a clinical point of view was that interstage deaths due to 
shunt complications decreased. Daily weight, which in previous reports has 
been reported as an important factor to improve survival [63, 139] has so far 
not been included which seem to be due to negative experience reported by 
parents.  
A statistical limitation of the study in Paper I was the small sized study 
population. We calculated that a study to show a 50 % decrease of mortality 
should take 15 years to complete at a single medium-sized institution like ours. 
In a country like Sweden, with a population of 10 million inhabitants and two 
surgical centers, studies like the one presented in Paper I have the risk of being 
under powered. There might be a difference but the number of patients is too 
small to reach statistical significance. The study designs in Paper II-V aimed 
to improve the statistical strength by adding cases from multiple centers as in 
Paper II and III or to use register data for complete national coverage with high 
validity data as in Paper IV and V.  
The advantage of multicenter studies in collecting a substantial number of 
cases in fetal cardiology has been discussed [140]. The aim of the study 
presented in Paper II was to collect cases of fetal aortic stenosis from multiple 
centers in Europe and to present outcome in relation to morphology and 
physiology. The condition is rare, and only a multicenter approach was 
considered when the study was designed. A major disadvantage of collecting 
data from multiple institutions is the problem of controlling for data quality, 
which might vary with the experience of the investigator and the technical 
equipment used. The most reliable predictive factor for univentricular outcome 
found in the studied cohort presented in Paper II was the size of the mitral 
valve, while physiological data were inconclusive. The validity and reliability 
of fetal echocardiography in research is not well studied and the effect of this 
possible limitation was difficult to fully appreciate.  
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The aim of the study in Paper III was to evaluate the efficacy of fetal 
valvuloplasty (FV) to achieve biventricular (BV) circulation and to improve 
survival. The result showed that there was no higher proportion of BV in the 
cohort that underwent FV compared to propensity score matched cases that did 
not undergo an intervention.  The early results of FV presented in the literature 
report that the first case series included hearts with left ventricles too small for 
a BV outcome also after an intervention [8, 98, 100]. The initial selection of 
cases could not be compensated for by the propensity score method. The lack 
of a treatment effect of FV on BV outcome might have been a result of 
including cases with too small left ventricles. We observed an effect on 
hemodynamic properties and the growth of left sided structures of the heart. 
The finding of improved intrinsic cardiac properties could explain the 
improved survival after FV compared to propensity score matched NH cases 
regardless of the final circulatory outcome.  
The overall survival for patients with fetal aortic stenosis and BV outcome 
studied in Paper II and III was lower compared to a cohort of patients with 
critical aortic stenosis with BV outcome in which the reported survival 
proportion was  89 % at 10 years [141]. A prenatal diagnosis of fetal aortic 
stenosis might suggest a more severe form of the disease compared to when 
the condition goes unnoticed during fetal life. The presence of a prenatal 
diagnosis was a significant risk factor for death (OR = 20, p = 0.01) in a 
cohort of neonates with critical aortic stenosis in which 14% had a prenatal 
diagnosis[142]. The proportion with BV outcome that survived to 5-years of 
age was comparably lower in the group of BV cases that underwent FV 
compared to cases in the NH cohort studied in Paper II. This was an expected 
finding since the BV cases undergoing FV should represent a more severe 
form of the disease. The survival was better after FV compared to NH in 
propensity score matched cases.  
The cohorts in Papers IV and V were identified through merged searches 
in national databases a search and matching of cases that was done manually. 
The final result, the complete national cohort of liveborn neonates with 
HLHS/AA, made it possible to observe the total outcome, not just the 
outcome for patients who underwent surgery. This approach was motivated 
because of the high pre-surgical mortality in HLHS/AA. The ICD-coding in 
national databases made it somewhat challenging to select cases with 
HLHS/AA rather than HLHS/AS since the ICD-code is HLHS with no 
further information on specific morphology. The selection of cases with AA 
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rather than AS was based on additional coding of AS or in cases that 
underwent surgery information in medical records. Some cases that possibly 
should have been included might have been excluded and vice versa. Overall, 
the process of selecting appropriate cases was meticulous and a case was 
excepted or excluded only if data was congruent in a least two databases.   
The incidence of HLHS/AA in Sweden in the first years of the study period 
was comparable with previously published data for populations without 
important prenatal detection and termination rates. The decrease in incidence 
was interpreted as the result of increased prenatal detection and termination 
rates. This assumption was supported by national reports on prenatal screening 
and terminations of pregnancy [45, 143, 144]. In Paper IV we introduced a 
model to estimated fetal incidence in order to show the shift from comfort care 
practiced to some extent in the early birth period to pregnancy terminations 
more commonly practiced in the late birth period. The model was an estimate, 
using the highest incidence of liveborn, and was aimed to demonstrate trends, 
not to calculate exact numbers. The proportions (not the numbers) were the 
same if an average of the first three years, or the highest incidence, was used. 
The highest incidence, 19 per 100,000, best corresponded to a detailed 
population based study performed at our institution covering the Western part 
of Sweden. The study included every prenatally and postnatally diagnosed case 
of HLHS/AA 2003-2010 with a fetal incidence of 20 per 100,000 (personal 
reference, not published).  
The finding that birth location influenced outcome (surgery versus no 
surgery) was first interpreted as different attitudes towards surgery at surgical 
centers compared to university hospitals without surgery. However, the effect 
disappeared when adjusting for prenatal diagnosis, a factor that was positively 
correlated to surgery versus no surgery in liveborn neonates. A prenatal 
diagnosis resulted most commonly in intrauterine transfer which explained the 
higher proportion of patients that underwent surgery of those born at a surgical 
center.  
The overall transplantation-free survival for the 121 patients with 
HLHS/AA who underwent the Norwood procedure 1993-2010 in Sweden was 
similar to previous reports with some variations. Earlier studies from two 
single centers reported the survival probability at 10-years to be 68-72 % for 
the same calendar period as studied in our report [72, 75]. The highest survival 
probability was observed in a cohort of standard risk neonates with prenatal 
diagnosis [72]. In a cohort including patients born before 1996 there was a 
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transplantation-free survival of 14 % at 18 years, which should reflect the 
earliest international results of the Norwood procedure for HLHS [71]. In our 
cohort presented in Paper V, the transplantation-free survival probability 
increased significantly between the two birth periods. The result observed in 
the later birth period corresponded to what should be expected as discussed 
above. The finding constitutes an important benchmark when comparing our 
national surgical programs with single-center experiences at large international 
centers.  
CONCLUSIONS AND FUTURE PERSPECTIVES 
HLHS and fetal AS are severe cardiac malformations with high mortality. 
Major achievements have been made in the past 20 years with improving 
survival as a result. Despite these improvements there is still a significant 
mortality and termination of pregnancy is common in Sweden if there is a 
prenatal diagnosis. Fetal valvuloplasty in aortic stenosis has a potential to 
promote growth and preserve cardiac function during pregnancy to enhance 
the chances of successful postnatal treatment and survival in cases with 
evolving HLHS.  
 
I. The vulnerable period between stage I and stage II in single 
ventricle palliation continue to be challenging. Improved 
anticoagulation therapies might be more efficient in preventing 
shunt occlusions with reduced risks. Optimal timing of stage II 
is important to ensure that the interstage period is not too short 
or too long.  
II. The improved ultrasound equipment available gives excellent 
insight into fetal cardiac development and growth. In 
populations where screening during pregnancy is widely 
practiced, a wide range of cardiac malformations will be 
detected. Further studies could give better indications of how to 
validate fetal echocardiographic data in research. Improved 
predictive models can be expected as more experience is gained.  
III. The future of fetal cardiac interventions for left-sided 
obstructive cardiac lesions is difficult to predict. So far, success 
has been limited to interventions performed by highly 
experienced teams who have treated a substantial number of 
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cases. In a Swedish perspective, future cases suitable for a fetal 
cardiac intervention will be referred to any of the larger 
international centers. The reports of improved hemodynamics 
and growth of the fetal heart after intervention make the method 
overall seem promising. If the method becomes more accepted 
among healthcare professionals, a future randomized controlled 
trial might be unethical to perform, since it would require a 
situation with clinical equipoise.  
IV. The incidence of HLHS/AA decreased over the study period. 
However, the trend noted after 2010 contradicts a continued 
decrease of incidence. The future perspective is that patients 
with HLHS/AA will continue to be born. A prenatal diagnosis 
will contribute to well-informed parents who are prepared to 
provide the best care for their children in cooperation with 
highly specialized professional teams.  
V. The future perspective for the cohort of HLHS/AA is optimistic 
in the sense that early survival has improved. Possibilities of 
further improving survival are not easily identified. Future 
efforts should focus on reducing morbidity and on supporting 
the patient’s neurocognitive development to provide the best 
possible quality of life for this group of patients.  
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SAMMANFATTNING PÅ SVENSKA 
 
Bakgrund 
Hypoplastiskt vänsterkammarsyndrom (HLHS) är ett allvarligt hjärtfel som 
är fatalt i nyföddhetsperioden om det nyfödda barnet inte omedelbart 
omhändertas och behandlas. Palliativ kirurgi har funnits tillgänglig i Sverige 
sedan 1993. Resultaten har förbättrats över tid men det är fortsatt ett hjärtfel 
med betydande mortalitet. Det har under senare år publicerats enstaka 
rapporter om att ballongdilatation hos foster med aortastenos kan förhindra 
uppkomst av HLHS i vissa utvalda fall. En annan metod för att förbättra 
överlevnaden hos födda barn är att övervaka dem mer noggrant även efter 
utskrivningen från sjukhus. Tidigare studier har visat på förbättrad 
överlevnad om syrgasmättnad och vikt kontrolleras dagligen av föräldrarna.  
 
Syfte med forskningen 
Syftet med de ingående arbetena i avhandlingen var att studera incidensen av 
hjärtfelet samt överlevnad efter kirurgi hos barn födde med HLHS ifrån 1990 
- 2010 i Sverige samt att studera om ballongdilatation av aortaklaffen hos 
foster med aortastenos kan förebygga uppkomsten av HLHS under den 
fortsatta graviditeten. Ett tredje syfte var att undersöka om hem-monitorering 
av syremättnaden i blodet en gång dagligen kunde förebygga dödsfall.  
 
Metoder 
En komplett nationell kohort med patienter med HLHS identifierades genom 
sökningar i nationella register. Förändringar av incidensen över tid samt 
transplantationsfri överlevnad beräknades och riskfaktorer för död 
analyserades. Naturalförloppet vid aortastenos hos foster samt betydelsen av 
ballongdilatation av aortaklaffen i fosterlivet studerades i två retrospektiva 
multicenterstudier i Europa. Hem-monitorering studerades i en experimentell 
studie och resultatet jämfördes med en historisk kohort.  
 
Resultat och konklusioner 
Den totala transplantationsfria överlevnaden för patienter med HLHS som 
genomgick kirurgi ökade från 40 % under åren 1993-2000 till 63 % under 
åren 2001-2010. Flickor visade sämre transplantationsfri överlevnad jämfört 
med pojkar. Incidensen minskade från 15,4 till 8,4 per 100 000 levande 
födda. Andel av levande födda som genomgick kirurgi ökade från 50 % till 
70 % mellan de studerade tidsperioderna. Ballongdilatation av aortaklaffen i 
fosterlivet förbättrade överlevnaden för levande födda men det kunde inte 
visas att det var en effekt av en lägre andel som utvecklade HLHS. De 
vänstersidiga hjärtstrukturernas tillväxt och funktion stimulerades hos foster 
som genomgick en intervention. Hem-monitorering av syremättnaden i 
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blodet bedömdes bidra till att rädda liv för ett antal individer men det var inte 
en statistiskt signifikant förbättrad överlevnad på gruppnivå i 
interventionsgruppen jämfört med historiska kontroller.   
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